EUCTR2021-003879-34-DE招募中1 期
Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients with Parkinson's Disease(ROCK-PD) - ROCK-PD
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients with a diagnosis of at least probable PD according to MDS criteria (Postuma et al. MovDis 2015) and
- •2. Hoehn & Yahr stage 1 – 3
- •3. must be non-fluctuating (no wearing-off, no dyskinesia) and stable on symptomatic PD medication for at least 6 weeks
- •4. age: 30 - 80 years
- •5. Women of childbearing age potential must be non-lactating and surgically sterile or using a highly effective method of birth control and have a negative pregnancy test. Acceptable methods of birth control with a low failure rate (i.e. less than 1% per year) when used consistently and correct are for example implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomized partner
- •6. Capable of thoroughly understanding all information given and giving full informed consent according to GCP
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 45
排除标准
- •1. Atypical, secondary Parkinsonian syndromes, PD mimics, or any other medical condition known to have an association with Parkinsonian syndromes, which might confound or obscure the diagnosis of PD
- •2. Patients with a history of intracranial bleeding, known intracerebral aneurysms or Moyamoya disease, or positive family history for the above. If only family history positive, MR- or x-ray-based cranial imaging not older than 24 months must confirm absence of bleeding, aneurysms, or Moyamoya
- •3. Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment
- •4. Patients with known arterial hypotension (resting blood pressure <90/60 mmHg) or previous hypotensive episodes or requiring treatment for increasing of blood pressure, such as fludrocortisone, midodrine, etilefrine, cafedrine, or theodrenaline
- •5. Patients with an uncontrollable or unstable arterial hypertensive disease (resting blood pressure >180 mmHg systolic and/or >120 mmHg diastolic under current antihypertensive medication)
- •6. Known pulmonary hypertension and any medication prescribed for treatment of pulmonary hypertension
- •7. Confirmed hepatic insufficiency or abnormal liver function (stable ASAT and/or ALAT greater than 3 times the upper limit of the normal range) and determined to be non-transient through repeat testing
- •8. Renal insufficiency with a glomerular filtration rate (GFR) <60 ml/min/1,73m² (calculated by MDRD equation) or XY (calculated by CKD-EPI equation) and determined to be non-transient through repeat testing
- •9. Major psychiatric disorder, significant cognitive impairment or clinically evident dementia precluding evaluation of symptoms
- •10. Hypersensitivity to any component of the IMP
- •11. Liable to be not cooperative or comply with the trial requirements (as assessed by the investigator), or unable to be reached in the case of emergency
- •12. Pregnant or breast-feeding females or females with childbearing potential, if no adequate contraceptive measures are used
- •13. Previous participation in another clinical study involving trial medication within the preceding 12 weeks or five terminal half times of the longest to be eliminated trial medications (whichever is longer) or previous participation in this trial
研究者
相似试验
Unknown
不适用
Comparative Efficacy, Safety And Tolerability Of Three Treatment Regiments For Uncomplicated Falciparum MalariaMalariaPACTR201802003020160SANOFI-SYNTHELABO750
已完成
2 期
This study is designed to compare the efficacy, safety and tolerability of two agents (topical Isotretinoin solution 0.1% and topical Adapalene gel 0.1%) in the Treatment of Acne Vulgaris commonly termed as pimples.CTRI/2011/05/001735Ranbaxy Laboratories Limited120
已完成
不适用
The evaluation of the efficacy and the safety of TSUMURA Tokishakuyakusan Extract Granules for Ethical Use on endometriosis patients with dysmenorrheaEndometriosisJPRN-UMIN000017908Tottori University Faculty of Medicine15
尚未招募
不适用
Comparison of two inject able iron preparations for treatment of iron deficiency anemia in pregnancyCTRI/2019/02/017553Department of Obstetrics and Gynecology
已完成
4 期
A clinical trial to study the effect of a Under eye Skin cream containing Biophytex LS 8740 and Proteasyl TP LS 8657 in patients with under eye dark circles.CTRI/2010/091/001346Glenmark Pharmaceutical limited500